SKB264 and glecirasib for advanced KRAS G12C lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced non-small cell lung cancer with a KRAS G12C mutation.
- You must not have had any prior treatment for advanced lung cancer (like chemotherapy, immunotherapy, or targeted therapy).
- You must be in good enough health to carry out daily activities (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on scans.
- Your blood counts and organ function (kidney, liver, heart) must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two new drugs, SKB264 and SKB118, for people with advanced non-small cell lung cancer. It may be an option if your cancer does not have the EGFR or ALK gene changes and you are in relatively good health.
This trial tests an oral targeted drug called Garsorasib for people with advanced lung cancer that has a specific KRAS G12C mutation and has not received previous treatment for advanced disease. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (Glecirasib and Ivonescimab) as the first treatment for people with non-small cell lung cancer that has a specific mutation called KRAS G12C and has spread or can't be removed by surgery. The goal is to see if this combination helps shrink tumors or slow the cancer down.
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
This trial tests a new approach for people with a specific type of lung cancer (KRAS G12C) that is still confined to the chest and can be surgically removed. It combines a targeted pill (garsorasib) followed by immunotherapy + chemotherapy before surgery, to see if this can shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.